Villasante FrickeACMitevaM.Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397-403.
2.
PapadopoulosAJSchwartzRAJannigerCK.Alopecia areata: pathogenesis, diagnosis, and therapy. Am J Clin Dermatol. 2000;1(2):101-105.
3.
CraiglowBGKingBA.Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134(12):2988-2990.
4.
CraiglowBGLiuLYKingBA.Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. 2017;76(1):29-32.
5.
GuptaAKCarvielJLAbramovitsW.Efficacy of tofacitinib in treatment of alopecia universalis in two patients. J Eur Acad Dermatology Venereol. 2016;30(8):1373-1378.
6.
JabbariANguyenNCeriseJEet al. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. Exp Dermatol. 2016;25(8):642-643.
7.
Kennedy CrispinMKoJMCraiglowBGet al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776.
8.
LiuLYCraiglowBGDaiFKingBA.Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76(1):22-28.
